BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
57.22
+0.72 (1.27%)
Jun 24, 2026, 11:44 AM EDT - Market open
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
VOXZOGO Revenue | 933.05M | 926.92M | 735.09M | ||||||||||||
VOXZOGO Revenue Growth | 0.66% | 26.10% | 56.44% | ||||||||||||
VIMIZIM Revenue | 813.91M | 792.05M | 739.78M | ||||||||||||
VIMIZIM Revenue Growth | 2.76% | 7.07% | 5.53% | ||||||||||||
NAGLAZYME Revenue | 501.18M | 485.40M | 479.58M | ||||||||||||
NAGLAZYME Revenue Growth | 3.25% | 1.21% | 14.11% | ||||||||||||
PALYNZIQ Revenue | 429.60M | 433.31M | 355.05M | ||||||||||||
PALYNZIQ Revenue Growth | -0.86% | 22.04% | 16.82% | ||||||||||||
ALDURAZYME Revenue | 196.27M | 208.51M | 183.89M | ||||||||||||
ALDURAZYME Revenue Growth | -5.87% | 13.39% | 40.11% | ||||||||||||
BRINEURA Revenue | 193.14M | 186.40M | 169.08M | ||||||||||||
BRINEURA Revenue Growth | 3.62% | 10.24% | 4.44% | ||||||||||||
KUVAN Revenue | 98.27M | 99.53M | 120.90M | ||||||||||||
KUVAN Revenue Growth | -1.26% | -17.68% | -33.12% | ||||||||||||
ROCTAVIAN Revenue | 27.77M | 35.64M | 26.07M | ||||||||||||
ROCTAVIAN Revenue Growth | -22.09% | 36.73% | 647.09% | ||||||||||||
Total Net Product Revenue | 3.19B | 3.17B | 2.81B | ||||||||||||
Total Net Product Revenue Growth | 0.80% | 12.75% | 18.41% | ||||||||||||
Royalty and Other Revenue | 49.12M | 53.49M | 44.47M | ||||||||||||
Royalty and Other Revenue Growth | -8.17% | 20.29% | -4.75% | ||||||||||||
Revenue (Other) | 7.00K | -4.00K | - | ||||||||||||
Revenue (Total) | 3.24B | 3.22B | 2.85B | ||||||||||||
Revenue (Total) Growth | 0.65% | 12.87% | 17.97% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
Royalty and Other Revenue | 49.12M | 53.49M | 44.47M | ||||||||||||
Royalty and Other Revenue Growth | -8.17% | 20.29% | -4.75% | ||||||||||||
United States Revenue | 1.11B | 1.10B | 924.81M | ||||||||||||
United States Revenue Growth | 0.11% | 19.48% | 19.90% | ||||||||||||
Europe Revenue | 863.59M | 874.33M | 829.03M | ||||||||||||
Europe Revenue Growth | -1.23% | 5.46% | 23.86% | ||||||||||||
Latin America Revenue | 455.36M | 435.48M | 378.08M | ||||||||||||
Latin America Revenue Growth | 4.57% | 15.18% | 13.73% | ||||||||||||
Rest of World Revenue (Post-Q2 2024) | 571.75M | 544.47M | 493.63M | ||||||||||||
Rest of World Revenue (Post-Q2 2024) Growth | 5.01% | 10.30% | 5.43% | ||||||||||||
Revenue (Other) | 196.28M | 208.51M | 183.89M | ||||||||||||
Revenue (Total) | 3.24B | 3.22B | 2.85B | ||||||||||||
Revenue (Total) Growth | 0.65% | 12.87% | 17.97% |